Top Markets
#1 Ontology Gas Ontology Gas +40.10%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.99%
#5 Geodnet Geodnet +14.90%
#6 ETHGas ETHGas +13.90%
#7 The Black Bull The Black Bull +12.16%
#8 Fake World Assets Fake World Assets +11.14%
#9 Curve DAO Curve DAO +10.88%
#10 Pons Pons +10.54%
Coin of the day
Ontology Gas Ontology Gas
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classifica tra le azioni #25521
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Prezzo delle azioni
$9.81
Ultima sincronizzazione: 2025-03-18
Capitalizzazione di mercato
$48.68M
Variazione (1 giorno)
1.55%
Variazione (1 anno)
0.00%
Paese
US
Scambia AlloVir, Inc. (ALVR)

Categoria

Healthcare
Utile per AlloVir, Inc. (ALVR)
Utile nel Jun 2026 TTM: $-54.46M
Secondo gli ultimi rapporti finanziari di AlloVir, Inc., gli utili attuali della società sono $-54.46M. Nel 2023, la società ha registrato un utile di $-190.54M, una diminuzione rispetto a agli utili del 2022, che erano di $-168.98M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di AlloVir, Inc. dal 2018 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -9,786.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,681.87%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -3,064.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 5,568.48%
US